Alaunos Therapeutics completed its acquisition of Velaris Therapeutics, exchanging shares for all outstanding equity interests. Concurrently, the company closed a private placement raising approximately $350 million from institutional investors led by Fairmount. The financing will fund Velaris's pipeline development and operations through 2029. Alaunos operates in the biotechnology sector.
